Placeholder Banner

BIO Submits Comments in Response to FDA Guidance on Digital Health Technologies

March 21, 2022

On Monday, March 21st, BIO submitted comments in response to the recent FDA draft guidance, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. In the comments submitted, BIO expressed appreciation for the issuance of this draft guidance as it provides greater clarity on FDA’s approach to the regulation of remote data acquisition, which will in turn encourage the use of digital health technologies (DHTs) and methods in product development. To further enhance this Guidance, BIO recommended that the Agency expound on the utility these technologies provide for facilitating better oversight of patients participating in remote studies, while allowing sponsors to collect data that is more relevant to patients’ needs. Additionally, though the Guidance encourages leveraging of prior work in verification and validation of DHTs, which will be critical as the field continues to advance; BIO noted that it does not provide specific evidentiary requirements for verification and validation, nor does it reference an available source as guidance. BIO urged the Agency to address these requirements in its final guidance. Furthermore, while the inclusion of topics such as data collection, storage, and protection in this guidance are helpful to sponsors; BIO encouraged the Agency to provide detail on specific issues like source data management, safeguards to ensure data integrity, expectations for raw data submission, and mitigation strategies for connectivity disruptions. Finally, BIO requested the Agency provide further clarity on how and when sponsors should engage with the various centers at FDA during development of a DHT for remote data acquisition in clinical trials.

Download Full Comments Below
BIO Comments on DHTs for Remote Data Acquisition
Discover More
On Monday, June 13th, BIO submitted comments in response to a recently published FDA draft guidance providing recommendations to sponsors on developing a Race and Ethnicity Diversity Plan to enroll adequate numbers of participants in clinical trials…
The Biotechnology Innovation Organization (BIO), BIO members and State affiliates urge immediate legislative action to repeal the harmful R&D amortization provision that went into effect earlier this year. The 2017 Tax Cuts and Jobs Act (TCJA)…
On Friday, June 10th, BIO submitted comments in response to the FDA’s draft guidance on developing human gene therapy products that incorporate genome editing (GE) of human somatic cells. Overall, BIO found the guidance to be a well-written resource…